Sign in
Not yet taking people in NetherlandsPhase 4

Tetanus booster vaccine to study immune cells in autoimmune disease patients

Tests a tetanus booster vaccine in adults with lupus, sclerosis or arthritis.

Key facts

Who runs it
Leids Universitair Medisch Centrum (LUMC)
Where
Leiden, NetherlandsSee the site
Registry title
Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response
Status
Not yet recruiting
Phase
Phase 4
People taking part
96 people, planned
Started
1 Oct 2025
Expected to end
30 Sept 2028
Type of study
Interventional
Record updated
8 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, and healthy volunteers. All get one tetanus booster vaccine so blood B cells can be studied.

Age
18 years or older
Sex
All sexes
Disease stage
Systemic sclerosis, systemic lupus erythematosus or rheumatoid arthritis, meeting the classification criteria for the diagnosis. Healthy volunteers can also join.
Earlier treatment
Must have finished the primary tetanus toxoid vaccination series. Must not have had B cell depleting or modifying therapy (Rituximab, Belimumab, Cyclophosphamide, Tocilizumab, Abatacept) in the 12 months before joining. Must not have had a tetanus vaccine or booster in the past 24 months.

Main reasons for not taking part

  • Pregnant at the time of joining
  • Allergy to the tetanus vaccine or its ingredients, or a severe reaction to an earlier dose
  • Tetanus vaccine or booster in the past 24 months
  • Treatment with Rituximab, Belimumab, Cyclophosphamide, Tocilizumab or Abatacept in the past 12 months
  • Needing to donate 50 mL of blood or more in the first four weeks for another reason

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • ≥ 18 years of age
  • able to understand the patient information form and to provide written informed consent
  • willing to receive a single, one-time booster vaccination against tetanus toxoid
  • having completed a primary vaccination regime against tetanus toxoid

Who cannot take part

  • individuals unwilling to provide sufficient information on their current health status required to assess eligibility, with the most relevant information being the presence/absence or prior history of an autoimmune disease, vaccination history, or the current or recent use of immunosuppressive drugs
  • who are or have been treated with specific B cell depleting/modifying therapies (Rituximab, Belimumab, Cyclophosphamide, Tocilizumab, Abatacept) within 12 months prior to inclusion
  • with contraindications for a booster vaccination against tetanus toxoid: o Hypersensitivity to the active substance(s) or to any of the excipients o Severe reaction after previous administration with the same vaccine
  • who received a TT vaccination or booster within the past 24 months prior to inclusion
  • who do not fulfill the classification criteria for the respective diagnoses, as set out in the inclusion criteria
  • for whom the treating physician considers that relevant safety issues apply (such as, for example, severe anemia) that preclude the provision of the required amount of peripheral blood projected for the study
  • who need to donate 50 mL of blood (or more) during the first four weeks of the study for any reason other than participation in the study (such as routine clinical care, participation in another study, blood donations for the blood bank, etc.)
  • who are pregnant at the time of inclusion

Where in Netherlands

  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

To induce, by booster vaccination, the activation of TT-specific B cells in order to compare the autoreactive B cell compartment with the resting and activated TT-specific B cell compartment over time in patients with autoimmune diseases and healthy individuals.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response
Plain-language title
Tetanus booster vaccine to study immune cells in autoimmune disease patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
8 July 2025